What is Kala Bio?
Headquartered in Arlington, Massachusetts, and established in 2009, Kala Bio operates as a specialized biopharmaceutical entity dedicated to the research, development, and commercialization of innovative therapeutics. The company leverages proprietary technology platforms to address unmet medical needs, positioning itself as a critical player in the development of ocular and systemic treatments. Its market position is defined by a rigorous adherence to clinical excellence and a strategic focus on translating scientific discovery into viable, patient-centric medical products.
How much funding has Kala Bio raised?
Kala Bio has raised a total of $104.8M across 4 funding rounds:
Stock Offering
$90M
Share Placement
$10.8M
Stock/Share Issuance
$2.3M
Stock/Share Issuance
$1.8M
Stock Issuance/Offering (2017): $90M, investors not publicly disclosed
Share Placement (2024): $10.8M, investors not publicly disclosed
Stock/Share Issuance (2026): $2.3M, investors not publicly disclosed
Stock/Share Issuance (2026): $1.8M, investors not publicly disclosed
Key Investors in Kala Bio
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Kala Bio?
With the recent influx of capital, Kala Bio is well-positioned to accelerate its late-stage clinical programs and expand its commercial footprint. The strategic allocation of these funds will likely prioritize the scaling of manufacturing capabilities and the enhancement of its research infrastructure to support upcoming regulatory milestones. As the company transitions into this next phase of enterprise-level operations, the focus will remain on optimizing its therapeutic portfolio to ensure sustainable growth and long-term value creation for stakeholders. The firm's ability to secure consistent financing serves as a testament to its operational resilience and its potential to disrupt existing treatment paradigms in the biopharmaceutical market.
See full Kala Bio company page
